Rifamycin, 4-O-(Carboxymethyl)-1-deoxy-1,4-dihydro-4-hydroxy-1-oxo-, γ-Lacton
|
|
|
- CAS-Nr.
- 14487-05-9
- Bezeichnung:
- Rifamycin, 4-O-(Carboxymethyl)-1-deoxy-1,4-dihydro-4-hydroxy-1-oxo-, γ-Lacton
- Englisch Name:
- Rifamycin O
- Synonyma:
- ctone;NSC 182391;RIFAMYCIN O;Rifomycin O;Levofloxacin O;Rifamycin O USP/EP/BP;Rifaximin EP Impurity F;Rifamycin EP Impurity C;Rifaximin impurity F (EP);Rifaximin EP Impurity F (Rifamycin O)
- CBNumber:
- CB9404663
- Summenformel:
- C39H47NO14
- Molgewicht:
- 753.79
- MOL-Datei:
- 14487-05-9.mol
|
Rifamycin, 4-O-(Carboxymethyl)-1-deoxy-1,4-dihydro-4-hydroxy-1-oxo-, γ-Lacton Eigenschaften
- Schmelzpunkt:
- 171°C (dec.)
- alpha
- D20 +71.5° (c = 1 in dioxane)
- Siedepunkt:
- 730.16°C (rough estimate)
- Dichte
- 1.2421 (rough estimate)
- Brechungsindex
- 1.5350 (estimate)
- storage temp.
- -20°C Freezer, Under Inert Atmosphere
- L?slichkeit
- Chloroform (Slightly), Methanol (Slightly, Heated )
- Aggregatzustand
- Solid
- pka
- 4.61±0.70(Predicted)
- Farbe
- Yellow to Dark Yellow
- InChIKey
- RAFHKEAPVIWLJC-QZBGMZITNA-N
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
Rifamycin, 4-O-(Carboxymethyl)-1-deoxy-1,4-dihydro-4-hydroxy-1-oxo-, γ-Lacton Chemische Eigenschaften,Einsatz,Produktion Methoden
Chemische Eigenschaften
Yellow Solid
Verwenden
Rifamycin O (Rifaximin EP Impurity F) is a Rifaximin intermediate.
Rifamycin, 4-O-(Carboxymethyl)-1-deoxy-1,4-dihydro-4-hydroxy-1-oxo-, γ-Lacton Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Rifamycin, 4-O-(Carboxymethyl)-1-deoxy-1,4-dihydro-4-hydroxy-1-oxo-, γ-Lacton Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 151)Lieferanten
14487-05-9(Rifamycin, 4-O-(Carboxymethyl)-1-deoxy-1,4-dihydro-4-hydroxy-1-oxo-, γ-Lacton)Verwandte Suche:
Rifamycin, 1,4-Dideoxy-1,4-dihydro-1,4-dioxo-
Rifamycin, Natriumsalz
Rifamycin, 4-O-(Carboxymethyl)-
Rifamycin
Rifapentin
Rifampicin
Rifamycin, 3-Formyl-
2-Vinyl-1,3-dioxolan
Rifamycin, 4-O-(Carboxymethyl)-1-deoxy-1,4-dihydro-4-hydroxy-1-oxo-, γ-Lacton
2,5-Dimethyl-p-anisaldehyd
Riboflavin
2,4-Dimethylbenzylacetat
1,1'-(4,6-Dihydroxy-1,3-phenylen)bisethan-1-on
- ctone
- spiro(1,3-dioxolane-2,9’(6’h)-(2,7)(epoxypentadeca(1,11,13)trienimino)naphtho(
- 4-O-Carboxymethyl-1-deoxy-1,4-dihydro-4-hydroxy-1-oxorifamycin γ-lactone
- Rifomycin O
- NSC 182391
- 4-O-(CARBOXYMETHYL)-1-DEOXY-1,4-diHYDRO-4-HYDROXY-1-OXO-G-LACTONE
- RifaMycin,4-O-(carboxyMethyl)-1-deoxy-1,4-dihydro-4-hydroxy-1-oxo-, g-lactone
- Rifaximin EP Impurity F
- Rifamycin, 4-O-(carboxymethyl)-1-deoxy-1,4-dihydro-4-hydroxy-1-oxo-, gamma-lactone
- RIFAMYCIN O
- 2,1-b)furan)-1’,4,6’,11’(2’h)-tetrone,5’,17’,19’,21’-tetrahydroxy-23’-methoxy
- 4’,12’,16’,18’,20’,22’-heptamethyl--221’-acetate
- 4-o-(carboxymethyl)-1-deoxy-1,4-dihydro-4-hydroxy-1-oxo-rifamycigamma-la
- Rifaximin impurity F (EP)
- Rifaximin Impurity 6 (Rifaximin EP Impurity F)
- Rifamycin EP Impurity C
- Rifaximin EP Impurity F (Rifamycin O)
- Rifamycin, 4-O-(carboxymethyl)-1-deoxy-1,4-dihydro-4-hydroxy-1-oxo-, γ-lactone
- Rifamycin Impurity 3(Rifamycin EP Impurity C)（Rifamycin O)
- Rifamycin O USP/EP/BP
- Spiro[1,3-dioxolane-2,9'(6'H)-[2,7](epoxypentadeca[1,11,13]trienimino)naphtho[2,1-b]furan]-1',4,6',11'(2'H)-tetrone, 5',17',19',21'-tetrahydroxy-23'-methoxy-2',4',12',16',18',20',22'-heptamethyl-21'-acetate
- Rifamycin, 4-O-(carboxymethyl)-1-deoxy-1,4-dihydro-4-hydroxy-1-oxo-, γ-lactone (9CI, ACI)
- 4-O-(carboxymethyl)-1-deoxy-1,4-dihydro-4-hydroxy-1-oxo-Rifamycin γ-lactone (9CI ACI)
- Rifaximin EP Impurity F（Rifamycin EP Impurity C）
- Spiro[1,3-dioxolane-2,9'(6'H)-[2,7](epoxypentadeca[1,11,13]trienimino)naphtho[2,1-b]furan]-1',4,6',11'(2'H)-tetrone, 5',17',19',21'-tetrahydroxy-23'-methoxy-2',4',12',16',18',20',22'-heptamethyl-21'-acetate
- Levofloxacin O
- 14487-05-9
- C39H47NO14
- Chiral Reagents
- Intermediates & Fine Chemicals
- Pharmaceuticals
